share_log

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $21

BTIG Maintains Buy on Health Catalyst, Lowers Price Target to $21

BTIG 维持对健康催化剂的买入,将目标价下调至21美元
Benzinga Real-time News ·  2022/09/26 08:13

BTIG analyst David Larsen maintains Health Catalyst (NASDAQ:HCAT) with a Buy and lowers the price target from $25 to $21.

BTIG分析师戴维·拉森维持Health Catalyst(纳斯达克股票代码:HCAT)的买入并将目标股价从25美元下调至21美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发